The biology behind the disease explains why the new drugs work the way they do. Transthyretin is a transport protein produced almost entirely in the liver, circulating in the blood as a four-part tetramer that carries thyroxine and retinol-binding protein. In ATTR amyloidosis, the tetramer dissociates into individual subunits that misfold and aggregate into insoluble fibrils that deposit in the myocardium. Dissociation of the tetramer is the rate-limiting step of this amyloidogenic cascade, which is precisely where the first drug class intervenes. Tafamidis, approved in Germany in 2020, and acoramidis, approved in 2025, are so-called kinetic stabilizers that selectively bind to the unoccupied thyroid hormone-binding site of the tetramer, locking it shut and preventing the misfolding that leads to amyloid deposition.

The second class attacks the problem upstream. Vutrisiran, a small interfering RNA approved for ATTR-CM in 2025, is a double-stranded RNA molecule conjugated to a sugar that escorts it into liver cells, where it binds the messenger RNA encoding transthyretin and triggers its degradation. The result is a marked, durable reduction in hepatic production of the precursor protein, with a mean maximum TTR reduction of 57 to 97 percent sustained for at least 90 days after each subcutaneous injection. Rather than stabilizing the protein that already exists, vutrisiran essentially shuts down the factory, and clinical outcomes in the phase 3 HELIOS-B trial now document what that pharmacologic logic delivers in patients.

The evidence base for all three drugs rests on landmark randomized trials, each with its own design and population. For tafamidis, the pivotal ATTR-ACT trial randomized 441 patients, predominantly older men with the wild-type form of the disease, to drug or placebo on top of standard heart failure therapy. Over 30 months, tafamidis significantly reduced the hierarchical composite of all-cause mortality and cardiovascular hospitalization, with an absolute mortality reduction of 13.4 percent and a strikingly low number needed to treat of eight. Long-term extension analyses confirmed a sustained survival benefit beyond five years for patients who started tafamidis early, compared to those who began therapy only after the trial ended. That pattern, in which delayed treatment never fully caught up, has become the most consistent lesson across the entire field.

Acoramidis, designed to mimic the super-stabilizing T119M transthyretin variant, produced one of the most compelling results in the ATTRibute-CM trial. In a modified intention-to-treat population of 611 patients followed for 30 months, acoramidis achieved a win ratio of 1.8 on a hierarchical endpoint combining mortality, cardiovascular hospitalizations, NT-proBNP change and six-minute walk distance. Although the mortality effect alone did not reach statistical significance at 30 months, it did so after 42 months in the open-label extension, with a hazard ratio of 0.64. Notably, treatment with acoramidis raised serum TTR levels early, and each 5 milligrams per deciliter increase in TTR was associated with a 31.6 percent reduction in the risk of all-cause mortality, an observation the panel considers an important pharmacodynamic signal for monitoring therapy.

Vutrisiran’s HELIOS-B trial extended the gene-silencing approach to the cardiomyopathy population with equally impressive results. Over approximately 33 months, vutrisiran reduced the composite of all-cause mortality and recurrent cardiovascular events by 25 to 30 percent in relative terms, and cut all-cause mortality by roughly one third at 42 months. Patients on vutrisiran preserved walking distance, experienced attenuated rises in NT-proBNP detectable as early as six months, and maintained quality of life scores that placebo patients lost. The benefits were most pronounced in patients on monotherapy and in those with less advanced disease, reinforcing the same theme: intervene early, because amyloid burden accumulated before treatment may never be fully recovered.

Given the absence of any head-to-head trial between the three agents, the panel’s central conclusion is deliberately cautious: based on current scientific data, tafamidis, acoramidis and vutrisiran are considered similarly effective for most patients with confirmed ATTR-CM. All three demonstrated significant reductions in all-cause mortality and cardiovascular hospitalizations in their respective phase 3 studies, with comparable tolerability profiles. The one clear exception concerns patients with hereditary ATTR-CM and a mixed phenotype, meaning concurrent cardiomyopathy and polyneuropathy, for whom the panel recommends vutrisiran as first-line therapy, based on its demonstrated efficacy against both cardiac and neurological manifestations in the HELIOS-A and HELIOS-B programs.

Safety data, while reassuring for all three agents, differ in the details that matter for individual patients. Tafamidis is generally well tolerated, with mild gastrointestinal symptoms such as diarrhea and constipation as the most frequent complaints, and a permanent discontinuation rate of only 0.8 percent in the pivotal trial. Acoramidis also showed a favorable profile, though mild to moderate gastrointestinal effects including diarrhea, nausea and dyspepsia occurred more frequently than with placebo, and gout was observed more often in treated patients. An early, reversible rise in serum creatinine was noted, but renal pharmacokinetics were not meaningfully affected and no dose adjustment is required. Vutrisiran, administered subcutaneously every three months, showed a safety profile comparable to placebo across age groups, with transient injection-site reactions in about 2 percent of patients, though patients require daily vitamin A supplementation of 2500 international units, typically at their own expense in Germany, because gene silencing also reduces this essential nutrient’s transport protein.

The consensus document goes well beyond pharmacology, addressing the practical realities that determine whether patients actually receive treatment. Annual therapy costs in Germany currently range from approximately 100,000 to 150,000 euros per patient, a figure that fell after a 50 percent price reduction for vutrisiran at the end of 2025 but still raises serious cost-effectiveness concerns, given that the median age at diagnosis is around 80 years. The authors note that prescribing is almost exclusively concentrated in specialized amyloidosis centers, creating bottlenecks that delay diagnosis and treatment and worsen prognosis. To counter this, the panel proposes a shared care model in which centers establish the diagnosis and initiate therapy, while trained office-based physicians handle routine monitoring and ongoing prescriptions. Early initiation, the authors emphasize, matters far more than the specific choice of substance, since open-label extension data consistently show that patients who started therapy late never regained the survival advantage of those treated from the beginning.

For patients in whom therapy is already underway, the consensus defines multimodal criteria for recognizing disease progression, including heart failure hospitalization, diuretic intensification, NT-proBNP increases above 700 picograms per milliliter with a relative rise exceeding 30 percent, eGFR declines greater than 20 percent, worsening quality of life scores, or NYHA class deterioration. Fulfillment of at least two criteria after 12 months of adequate therapy, without another identifiable cause, may prompt consideration of switching substance or class, although the panel acknowledges that prospective data to guide such switches do not yet exist. As a rule of thumb, specific therapy requires two to three years to deliver significant prognostic benefit, meaning patients with a life expectancy under two years are unlikely to benefit and should instead receive optimal supportive care. The panel also cautions against combination therapy, which appears safe but lacks randomized evidence of incremental efficacy, and points to a rich pipeline of future options, including the antisense oligonucleotide eplontersen, the NSAID-derived stabilizer diflunisal, CRISPR-Cas9 gene editing with nexiguran ziclumeran, and amyloid-depleting antibodies such as NI006, which in early trials demonstrated actual removal of cardiac amyloid deposits. For a disease once written off as untreatable, the consensus marks less an endpoint than a beginning.

Subject of Research: Expert consensus recommendations for disease-modifying drug treatment of transthyretin amyloid cardiomyopathy in Germany

Article Title: Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK)

Article References: aus dem Siepen, F., Trenkwalder, T., Aßmus, B., Kindermann, I., Lavall, D., Spethmann, S., Michel, L., Hansen, T., Kruck, S., Rischpler, C., Knebel, F., Schwarting, S. K., Bavendiek, U., Papathanasiou, M., Hegenbart, U., Yilmaz, A., Hahn, K., Carpinteiro, A., Pfister, R., & Morbach, C. (2026). Specific treatment of ATTR-CM in Germany—expert consensus of the German Society of Amyloid Diseases (DGAK) and German Cardiac Society (DGK). Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03006-1

Image Credits: AI Generated

DOI: 10.1007/s00392-026-03006-1

Keywords: ATTR-CM, transthyretin amyloid cardiomyopathy, tafamidis, acoramidis, vutrisiran, amyloidosis, heart failure, TTR stabilizers, gene silencing, DGAK, DGK, expert consensus

The new research, conducted at the Unidade Corino de Andrade in Porto, Portugal, one of the world’s principal referral centers for the condition, followed 151 patients carrying the V30M mutation, the variant responsible for the large endemic focus of the disease in northern Portugal. All participants were systematically evaluated for a spectrum of central nervous system manifestations, including transient focal neurological episodes, headaches, seizures, stroke, and symptoms of cranial nerve dysfunction. The results, published in the Journal of Neurology, reveal that nearly one in three patients had experienced transient focal neurological episodes, brief spells of cortical dysfunction that can mimic small strokes, while close to a quarter reported recurrent headaches and nearly seven percent had suffered seizures.

The mechanism behind these symptoms is a form of cerebral amyloid angiopathy specific to transthyretin. Although current disease-modifying therapies, from liver transplantation to tafamidis and gene-silencing drugs, act on the liver to suppress or stabilize the circulating form of the protein, the choroid plexus inside the brain continues to produce its own transthyretin, which is secreted directly into the cerebrospinal fluid. This intrathecal production is essentially untouched by liver-directed treatments. Over years, the protein deposits in the leptomeningeal membranes and arteries, particularly around the brainstem and spinal cord, gradually stiffening and damaging the vessels that bathe the brain’s surface.

The study’s most striking finding concerns the relationship between disease duration and brain symptoms. Transient focal neurological episodes were virtually absent in patients within their first five years of illness, but their prevalence climbed steadily with time, reaching more than seventy percent among those living with the disease for over two decades. When researchers dichotomized the cohort at fifteen years of disease duration, the difference was stark: fewer than eight percent of patients with shorter disease duration reported a history of these episodes, compared with just over half of those with longer disease. In statistical models, disease duration greater than fifteen years carried nearly a sixfold increase in the odds of having experienced such episodes, an association that remained robust after adjustment for age, sex, treatment category, and disease severity.

These episodes themselves are clinically distinctive and troubling. Most patients reported recurrent attacks, with a median of ten episodes per person, lasting around fifteen minutes. Language dysfunction was the most common manifestation, followed by sensory disturbances, and the majority of patients experienced more than one type of symptom. Crucially, most episodes involved a temporary loss of function, such as weakness or numbness, rather than positive phenomena like tingling or jerking. This makes them nearly impossible to distinguish from transient ischemic attacks on clinical grounds alone, a diagnostic dilemma the researchers emphasize repeatedly. Because recurrence is the main differentiating feature, the team advises that any first episode should prompt a full stroke work-up, including brain magnetic resonance imaging whenever feasible.

Yet the picture may differ from the cerebral amyloid angiopathy caused by amyloid-beta, the protein implicated in Alzheimer’s disease and sporadic cerebral amyloid angiopathy. In that condition, transient focal neurological episodes are strongly linked to superficial siderosis, a chronic accumulation of blood products on the brain’s surface, and to a high risk of devastating lobar hemorrhages. In transthyretin amyloidosis, neuropathological studies from Portugal have found superficial siderosis in only a small minority of cases, and brain imaging studies of patients with these episodes, including those from the present cohort, have frequently shown no hemorrhagic or ischemic lesions despite clear evidence of amyloid deposition on PET scans. This raises the possibility that the transient episodes arise from a different mechanism, perhaps cortical spreading depression or focal seizure activity, rather than from the vessel rupture seen in other amyloid conditions.

The study also broadened the recognized symptom spectrum beyond transient episodes. Nearly forty percent of patients reported symptoms attributable to cranial nerve dysfunction, most commonly reduced smell, followed by hearing loss and tinnitus. On bedside examination, objective hearing loss was detected in almost a quarter of participants and was associated with both older age and longer disease duration, findings that align with the dense amyloid deposition these patients often show around the brainstem, where cranial nerves exit. Headaches were also frequent, though the overall prevalence, including migraine-type headache, appeared similar to that of the general population. Symptomatic stroke, by contrast, was rare, occurring in only two patients, both with alternative explanations that may or may not have involved the underlying disease.

Therapeutic questions loom large over these findings. The researchers found that patients on tafamidis appeared less likely to report transient episodes in unadjusted analyses, but this association was heavily confounded by disease duration and treatment era, and it lost statistical significance after adjustment. Similarly, isolated case reports have described stabilization of central nervous system symptoms and improvement in leptomeningeal enhancement with gene-silencing therapies such as vutrisiran, despite the theoretical limitation of poor blood-brain barrier penetration. Notably, tafamidis has been detected in the cerebrospinal fluid at concentrations capable of partially stabilizing transthyretin, and higher doses approved for cardiac disease show stronger effects in laboratory assays. But no clinical trial has ever included central nervous system outcomes as endpoints, leaving the true effect of every available therapy on the brain essentially unknown.

The study also tested whether plasma neurofilament light chain, a widely used blood marker of axonal injury, could serve as a surrogate for brain involvement. The answer, at least for now, appears to be no. Baseline levels did not differ between patients with and without a history of transient episodes, and longitudinal measurements over twelve months showed no divergence in trajectory between the two groups. The researchers suggest that the substantial peripheral nerve damage characteristic of the disease may drown out any small central signal in the bloodstream, and they propose that cerebrospinal fluid neurofilament measurements might prove more informative. Alternatively, axonal injury may simply not be the central mechanism driving the brain complications.

The authors caution that their cohort consisted almost entirely of patients with early-onset V30M disease seen at a single center, and that survival bias cannot be excluded, since patients who died of catastrophic strokes would not have been recruited. Recall bias in self-reported transient symptoms is another limitation, though the researchers cross-checked patient accounts against medical records. Still, the consistency of the transient episode frequency with earlier studies lends credibility to the central conclusion: central nervous system assessment should become a routine component of follow-up care for patients with longstanding hereditary amyloidosis. As disease-modifying therapies extend survival, more patients are living long enough to enter the window in which brain involvement emerges, and the field urgently needs longitudinal studies, validated biomarkers, and clinical trials designed to answer whether current drugs can protect the brain as effectively as they protect the heart and the peripheral nerves.

Subject of Research: Central nervous system manifestations in hereditary transthyretin amyloidosis

Article Title: Central nervous system manifestations in hereditary transthyretin amyloidosis: a cross-sectional study with 151 patients

Article References: Sousa, L., Coelho, T., Fernandes, J., Cardoso, M., Alves, C., da Silva, A. M., Sousa, A. P., Pinto, M. M., Pereira, R. M., Ruano, L., Lemos, C., Baldeiras, I., Reis, C., & Taipa, R. (2026). Central nervous system manifestations in hereditary transthyretin amyloidosis: a cross-sectional study with 151 patients. Journal of Neurology, 273(10), Article 611. https://doi.org/10.1007/s00415-026-14146-9

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14146-9

Keywords: hereditary transthyretin amyloidosis, ATTRv amyloidosis, central nervous system, cerebral amyloid angiopathy, transient focal neurological episodes, V30M mutation, tafamidis, gene silencing therapy, neurofilament light chain, transthyretin, Journal of Neurology, Porto